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Abstract
Background: Imatinib represents the first in a class of drugs targeted against chronic myelogenous
leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR
kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the
oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia
cell line.
Results: We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib,
nilotinib, and dasatinib, and obtained IC50 values of 80 nM, 380 nM, and >100 μM, respectively.
Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation
of the protein environment around the flavin prosthetic group in NQO2. We have determined the
crystal structure of the complex of imatinib with human NQO2 at 1.75 Å resolution, which reveals
that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring. We find that
phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate
other aspects of NQO2 function.
Conclusion: The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits
NQO2 activity by competing with substrate for the active site. The overall conformation of
imatinib when bound to NQO2 resembles the folded conformation observed in some kinase
complexes. Interactions made by imatinib with residues at the rim of the active site provide an
explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib. These
interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1
by these compounds. Taken together, these studies provide insight into the mechanism of NQO2
inhibition by imatinib, with potential implications for drug design and treatment of chronic
myelogenous leukemia in patients.
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Chronic myelogenous leukemia (CML) is caused by
expression of a single oncoprotein resulting from the
fusion of the BCR and ABL genes [1]. The Abl protein is a
ubiquitously-expressed tyrosine kinase involved in multi-
ple signaling pathways, and the fusion of the Bcr protein
to the N-terminus of Abl in hematopoietic stem cells
results in an oncoprotein with unregulated tyrosine kinase
activity [2]. This causes cell proliferation, ultimately lead-
ing to leukemic transformation [3]. Imatinib (Gleevec,
STI-571) is a 2-phenylaminopyrimidine compound (Fig-
ure 1A) that represents the first in a class of targeted anti-
cancer drugs developed to treat CML through inhibition
of Bcr-Abl [4]. Due to the large number of kinases in the
human genome and the structural conservation of the
kinase catalytic domain, targeting specific kinases has
been particularly difficult. Nevertheless, imatinib is
remarkably specific, and is effective against a very limited
set of tyrosine kinases, including Kit, PDGFR and DDR in
addition to Abl [5].
A series of biochemical and structural studies have eluci-
dated the mechanisms responsible for the inhibition of
Abl by imatinib. Protein kinases generally adopt similar
active conformations, but can differ significantly in their
inactive conformations; imatinib inhibits Abl specifically
by binding to an inactive kinase domain conformation
that is characteristic of Abl [6-8]. The Kit kinase domain
also adopts an inactive conformation when bound to
imatinib, and this conformation resembles that of Abl
bound to imatinib [9,10]. Kit and PDGFR are now thera-
peutic targets of imatinib for tumor types in which they
are in a deregulated state [11,12].
Imatinib displays excellent efficacy and minimal side
effects in clinical studies with CML patients [13,14], and
now represents the frontline therapy for CML [15]. How-
ever, patients in advanced stages of the disease develop
resistance to imatinib treatment, due to the acquisition of
mutations in the Abl kinase domain that render the pro-
tein insensitive to this inhibitor [16,17]. Second-genera-
tion drugs such as nilotinib [18,19] and dasatinib [20]
(Figure 1A) have been developed that are able to target
most, but not all, imatinib-resistance mutations. Cur-
rently, third-generation therapeutic agents are in develop-
ment or clinical evaluation.
Inhibition of NQO2 by Abl kinase inhibitorsFigure 1
Inhibition of NQO2 by Abl kinase inhibitors. A) Chemical structures of the Abl kinase inhibitors imatinib, nilotinib, and 
dasatinib. Imatinib consists of a pyridine ring (A, green), an aminopyrimidine ring (B, blue), a methylbenzene ring (C, red), a ben-
zamide ring (D, magenta), and a N-methylpiperazine ring (E, orange). The structurally analogous rings of nilotinib and dasatinib 
are similarly labeled. B) NQO2 inhibition assays for kinase inhibitors imatinib (black circles), nilotinib (blue squares), dasatinib 
(green diamonds), and the flavonoid NQO2 inhibitor quercetin (magenta triangles). The data were fit to the concentration-
response equation , where x is the log of the inhibitor concentration, to yield IC50 values of 
42 nM, 82 nM, and 381 nM for quercetin, imatinib, and nilotinib, respectively. Dasatinib was a very poor inhibitor, with an IC50 
value > 100 μM.
activity IC= +
−
+ −
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tors is to maintain a degree of specificity similar to that of
imatinib for Abl, thereby minimizing potential side effects
from off-target interactions. Thus, to identify potential
secondary targets of these inhibitors, recent studies have
focused on chemical proteomics screens for drug-interac-
tors [21,22]. Briefly, the screens involve the generation of
matrix-linked inhibitors that are used to pull down inter-
acting proteins, which are then identified by mass spec-
trometry and validated by binding and activity studies.
This approach has been pursued with imatinib and the
second-generation inhibitors nilotinib, dasatinib, and
bosutinib. In addition to the known targets of these inhib-
itors, additional kinase targets were identified. For imat-
inib, the screens also identified a surprising non-kinase
target, the oxidoreductase NQO2, which also was shown
to be a target of the second-generation inhibitor nilotinib
but not dasatinib or bosutinib [21,22].
NQO2 is a cytosolic flavoprotein that carries out the 2-
electron reduction of quinones using electron donors
such as nicotinamide riboside (NRH). It is one of two
closely related cellular quinone reductases (the other
being NQO1) and is thought to be involved in metabolic
reduction and xenobiotic detoxification [23,24], although
its precise physiological role remains uncertain [25].
Interestingly, NQO2 is highly expressed in myeloid cells,
the targets of imatinib in CML anticancer therapy, and
RNAi knockdown of NQO2 in K562 cells, an immortal-
ized Bcr-Abl-positive CML cell line, resulted in reduced
proliferation rates [26]. The phosphorylation of NQO2
on a serine residue in K562 cells was observed [22], sug-
gesting potential regulation of the activity of the enzyme
by phosphorylation.
Imatinib and nilotinib inhibited the NQO2-mediated
reduction of the anticancer drug mitomycin C, with IC50
values of 1 μM for imatinib and 1.8 μM for nilotinib [21].
Another set of experiments demonstrated competitive
inhibition by imatinib of the NQO2-mediated reduction
of menadione (vitamin K3) with a Ki of 39 nM, in line
with an IC50 value of 43 nM obtained by competitive
binding assay [22]. These data, together with the observa-
tion that imatinib levels reach ~1 μM in the serum of
patients [14,27], imply that NQO2 inhibition occurs in
imatinib-treated CML patients, raising the possibility that
NQO2 inhibition may contribute to the overall pharma-
cological effects of these drugs.
The exact mechanism by which NQO2 is inhibited by
imatinib is unknown. Neither chemical proteomics study
detected turnover of imatinib by NQO2. One study pro-
posed that imatinib inhibits NQO2 activity via competi-
tion with the FAD cofactor for binding to the enzyme [21],
while the other study reported competitive inhibition
with respect to the substrate menadione [22].
Here, we report studies undertaken to further understand
the structural basis for the molecular mechanism by
which imatinib binds to and inhibits NQO2. Spectro-
scopic measurements confirmed the direct binding of
imatinib to NQO2, with concurrent changes in the flavin
environment indicating that the FAD is not displaced by
imatinib. We have solved the X-ray crystal structure of
NQO2 bound to imatinib to 1.75 Å resolution, which
shows that the drug is bound adjacent to the flavin iso-
alloxazine ring. The X-ray structure further provides an
explanation for the binding specificity of NQO2 for imat-
inib and nilotinib, as well as for the effects of mutation of
the reported phosphorylation sites on NQO2.
Results and discussion
Inhibition of NQO2 by imatinib and nilotinib
To assess the inhibition of NQO2 by imatinib, a continu-
ous spectrophotometric assay was used. Briefly, the
NQO2-mediated reduction of menadione to menadiol is
coupled to the reduction of the dye 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by
menadiol, resulting in an increase in absorbance at 590
nm. Nilotinib, dasatinib, and quercetin, a flavonoid
NQO2 inhibitor that is also a non-specific kinase inhibi-
tor [28], were included for comparison. As shown in Fig-
ure 1B, imatinib inhibited NQO2 activity with an IC50
value of 82 nM, approaching that observed for quercetin
(42 nM). These values are in the same range as those
determined previously [22,28]. Nilotinib inhibited
NQO2 activity with an IC50 value of 381 nM, while dasat-
inib did not inhibit NQO2 activity significantly at the
concentrations tested (IC50 > 100 μM).
Binding of imatinib to NQO2
To investigate the mechanism of inhibition of NQO2 by
imatinib, we first examined the effect of imatinib binding
on the flavin environment using electronic absorption
spectroscopy (Figure 2). The absorbance spectrum of the
enzyme in the absence of imatinib (Figure 2, solid line) is
characteristic of an oxidized flavoprotein [29], with
absorption bands at 454 and 389 nm and a shoulder at
477 nm. Upon addition of imatinib, the absorption
bands are perturbed significantly (Figure 2, dashed line)
and the difference spectrum exhibits minima at 389, 446,
and 475 nm and maxima at 496 and 560 nm (Figure 2,
inset). Thus, the flavin is affected appreciably by imatinib
binding, but not displaced from the protein, as the
observed spectrum in the presence of imatinib is not char-
acteristic of free flavin [30]. The results of our spectro-
scopic investigations are consistent with the notion that
imatinib competes with substrate for binding in the active
site adjacent to the flavin, as suggested previously [22].Page 3 of 12
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To determine how imatinib binds to NQO2, we crystal-
lized human NQO2 in the presence of imatinib and
solved the structure of the complex by molecular replace-
ment using the structure of the ligand-free enzyme (1QR2
[31]). The complex crystallized in space group I422, with
one monomer in the asymmetric unit. The crystals dif-
fracted x-rays to a resolution of 1.75 Å. Four N-terminal
residues (including two from a purification tag) and one
C-terminal residue are disordered. The final model
includes residues 3–230 of human NQO2, one FAD mol-
ecule, one imatinib molecule, one zinc atom, two (4R)-2-
methylpentane-2,4-diol (MRD) molecules, and 213 sol-
vent molecules. We use the same residue numbering
scheme for the model reported here that is used for all pre-
vious structures of NQO2, in which the genetically
encoded N-terminal methionine is excluded, so that the
second genetically encoded residue, Ala 2, is labeled as
residue 1 in the structure. The refined model has working
and free R-values [32] of 15.0% and 18.2%, respectively
(Table 1). 97.35% of observed backbone dihedral angles
lie in the favored Ramachandran regions, and the remain-
ing 2.65% lie in allowed Ramachandran regions.
Biochemical and structural studies have demonstrated
that NQO2 is a dimer [31,33]. In our structure, the dimer
is formed from two adjacent molecules related by a crys-
tallographic 2-fold axis. Dimerization leads to formation
of two FAD-containing active sites per dimer, with each
active site located in a deep pocket at the interface
between monomers (Figure 3A). Clear density into which
imatinib could easily be built was observed in the electron
density maps at the active site after molecular replacement
(Figure 3B). Imatinib interacts with NQO2 primarily via
hydrophobic interactions, as shown in Figure 4A. The iso-
alloxazine ring of the flavin cofactor forms the floor of the
Binding of imatinib to NQO2F gure 2
Binding of imatinib to NQO2. Binding of imatinib to NQO2 causes significant changes in the electronic absorption spec-
trum of the flavin cofactor. Shown is the spectrum of 18.3 μM NQO2 in the absence (solid line) and presence (dashed line) of 
40 μM imatinib at 25°C. Inset, difference spectrum calculated by subtraction of the spectrum of the unbound protein from that 
of the imatinib-bound protein.Page 4 of 12
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Table 1: Crystallographic data and refinement statistics
Data collection
Beamline ALS 8.2.1
Wavelength (Å) 1.2547
Space group I422
Unit cell a = 100.3 Å, b = 100.3 Å, c = 104.9 Å
α = 90°, β = 90°, γ = 90°
Resolution (Å)* 36.25–1.75 (1.84–1.75)
Rmerge (%)* 8.3 (55.9)
I/σ (I) * 22 (3.9)
Completeness (%)* 99.9 (99.9)
Redundancy* 9.2 (9.3)
Refinement
Unique reflections 27265
Free R test set (% of total data) 5.12
Rwork/Rfree (%) 15.0/18.2
Monomers per asymmetric unit 1
Number of non-hydrogen atoms 2166
Protein 1847
Ligand (imatinib, FAD, MRD) 106
Water 213
r.m.s. deviation, bond lengths (Å) 0.012
r.m.s. deviation, bond angles (Å) 1.093
* Outer resolution shell and statistics for that shell are in parentheses
Structure of NQO2 in complex with imatinibFigure 3
Structure of NQO2 in complex with imatinib. A) Cartoon representation of the NQO2 dimer bound to imatinib. The 
two monomers (colored green and orange) are related by a crystallographic two-fold axis of rotation. B) Difference electron 
density (contoured at 3.0 σ) from a map calculated with the imatinib ligand removed is shown over the refined model of the 
imatinib-bound NQO2. In each panel, the FAD and imatinib molecules are depicted as yellow and blue stick figures, respec-
tively; carbon is colored yellow (FAD) or light blue (imatinib); nitrogen, blue; oxygen, red; phosphorus, orange. Bound zinc ions 
are shown as grey spheres.
BMC Structural Biology 2009, 9:7 http://www.biomedcentral.com/1472-6807/9/7active site, upon which the pyridine and pyrimidine rings
(rings A and B) of the bound imatinib stack, with an aver-
age distance of ~3.3 Å between atoms in closest contact.
The side chains of Trp 105 and Phe 106 form the back of
the active site, while three hydrophobic amino acids from
the other monomer in the NQO2 dimer, Phe 126, Ile 128,
and Phe 178, form the top of the active site (Fig 4B).
Steric constraints prevent the bound imatinib from bind-
ing in an extended conformation, causing it to instead
adopt a horseshoe shape that directs the methylbenzene,
benzamide, and N-methylpiperazine rings (rings C, D and
E) away from the active site and towards the solvent (Fig-
ure 4C). The imatinib N-methylpiperazine ring extends
into solvent and forms crystal contacts with a third sym-
metry-related molecule.
The inhibitor makes no direct hydrogen bonds with the
protein, although several water-mediated hydrogen
bonds are observed. A water-mediated hydrogen bond is
formed between Asn 161, which is positioned by a hydro-
gen-bonding interaction with Tyr 132, and the N3 nitro-
gen of the imatinib pyridine ring (ring A). The N8 and
N13 nitrogen atoms of the imatinib 2-aminopyrimidine
moiety (ring B) interact with a cluster of ordered waters
(Figure 4B). A similar water cluster is also observed in sev-
eral other NQO2-ligand complexes [26,34], and such
water-mediated interactions have been proposed to be
important for NQO2 ligand recognition [31,35].
Substrates and inhibitors of NQO2 contain planar aro-
matic moieties that insert into the active site and stack on
the isoalloxazine ring of the flavin cofactor [26,31,34-37]
Figure 4
Interactions of imatinib with NQO2Figure 4
Interactions of imatinib with NQO2. A) Schematic of 
imatinib-NQO2 interactions. Van der Waals interactions of 
imatinib with NQO2 residues are indicated as semi-circles, 
and hydrogen bonds are represented by dotted lines. Con-
tacts from each NQO2 monomer are colored green or 
orange. B) Residues involved in contacts between imatinib 
and NQO2 are primarily hydrophobic interactions. One 
water-mediated hydrogen bond is formed between imatinib 
and the side chain of Asn 161, which is positioned by a 
hydrogen-bonding interaction with Tyr 132. Residues 
involved in contacts between imatinib and NQO2 are shown 
as stick figures, and water molecules are shown as red 
spheres. Not shown: Gly 149, Gly 150, Thr 151, and Ile 194. 
C) Surface representation of the active site of NQO2 in 
complex with the kinase inhibitor imatinib. In each panel, the 
FAD and imatinib molecules are depicted as yellow and blue 
stick figures, respectively; nitrogen is colored blue and oxy-
gen, red. Water molecules are shown as red spheres. The 
imatinib rings are lettered as in Figure 1A.Page 6 of 12
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BMC Structural Biology 2009, 9:7 http://www.biomedcentral.com/1472-6807/9/7(Figure 5A). For imatinib this role is played by the 4-pyri-
dyl-2-aminopyrimidine moiety (rings A and B). Because it
is substantially larger than previously characterized
NQO2 ligands, imatinib forms additional interactions,
including hydrophobic interactions between the methyl-
benzene, benzamide, and N-methylpiperazine rings
(rings C, D and E) and several amino acids surrounding
the rim of the active site (Figure 5B).
Discrimination by NQO2 between imatinib, nilotinib and 
dasatinib
The imatinib binding mode we observe in our structure
explains why NQO2 is inhibited by nilotinib, but not by
dasatinib [21]. Nilotinib contains a 4-pyridyl-2-phe-
nylaminopyrimidine core (nilotinib rings A, B and C, Fig-
ure 1A), identical to that of imatinib, that can adopt a
planar conformation and fit in the active site, and a simi-
lar amide-linked substituted phenyl ring (nilotinib ring D,
Figure 1A), which likely also extends towards solvent from
the active site. The modest reduction in affinity relative to
imatinib may be due to the increased bulk and decreased
flexibility of the nilotinib trifluoromethylbenzene and
methylimidazole rings (nilotinib rings D and E, Figure
1A) compared to the benzamide and N-methylpiperazine
rings of imatinib (imatinib rings D and E, Figure 1A). The
chemical structure of dasatinib contains an aminopyrimi-
dine core similar to that of imatinib and nilotinib (dasat-
inib ring B, Figure 1A), but the adjacent non-aromatic
hydroxyethylpiperazine ring (dasatinib ring A, Figure 1A)
cannot adopt the planar conformation necessary for stack-
ing onto the flavin isoalloxazine ring. Dasatinib is unable
to adopt a cis conformation (see the kinase discussion
below for an explanation) around the bond between the
aminopyrimidine and thiazole rings (dasatinib rings B
and C, Figure 1A) that is capable of productive interaction
with the rim of the active site.
Specificity of imatinib for NQO2 over NQO1
NQO2 is closely related to another quinone reductase,
NQO1. Despite catalyzing the same reaction, namely, the
two-electron reduction of quinones, and sharing 49%
identity at the amino acid level [33], NQO1 is not inhib-
ited by imatinib [22]. A comparison of the structures of
human NQO1 [38] with the structure of imatinib-bound
NQO2 described here provides an explanation for this
observation. While the structures of NQO1 and NQO2
superimpose well, with a r. m. s. deviation of 0.770 Å over
220 Cα atoms, NQO2 lacks a C-terminal domain of 43
amino acids. The C-terminal domain of NQO1 is
involved in binding of the adenosine and diphosphate
moieties of the cosubstrate NAD(P)H, which is not used
by NQO2 [28,39]. When the two structures are superim-
Comparison between binding of imatinib and other small molecules to NQO2Figure 5
Comparison between binding of imatinib and other small molecules to NQO2. A) Overlay of the structures of sev-
eral substrate- and inhibitor-NQO2 complexes with the imatinib-NQO2 complex. The loop containing Asn 161 has been 
removed for clarity. All of the bound molecules contain aromatic rings that stack above the flavin isoalloxazine group. B) The 
same overlay as in A), rotated to show interactions of the imatinib methylbenzene, benzamide, and N-methylpiperazine rings 
with hydrophobic residues (shown as CPK models) around the rim of the NQO2 active site. In each panel, imatinib (blue), the 
FAD cofactor (yellow), and several residues important for inhibitor binding are shown as stick figures, while the other overlaid 
NQO2-bound molecules are shown as line figures. The imatinib rings are lettered as in Figure 1A. The other molecules are 
menadione (magenta), resveratrol (pink), adrenochrome (grey), dopamine (green), melatonin (orange), and CB1954 (teal), 
from PDB ID 2QR2[31], 1SG0[26], 2QMY[37], 2QMZ[37], 2QWX[35], and 1XI2[36], respectively.Page 7 of 12
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domain of NQO1 occupies the space in which the imat-
inib N-methylpiperazine ring (ring E, Figure 6) is found in
the NQO2 structure. In addition, the side chains of Tyr
128 and Pro 68 at the rim of the NQO1 active site occlude
the space that is occupied in the NQO2 structure by the
imatinib benzamide and methylbenzenes rings (rings D
and C), respectively, and the side chain hydroxyl group of
Tyr 126 clashes with the imatinib aminopyrimidine ring
(ring B). Thus, steric hindrance by residues in the C-termi-
nal domain unique to NQO1, and by residues in the
active site that differ between NQO1 and NQO2, prevents
imatinib binding in the NQO1 active site.
Comparison of the imatinib binding modes observed in 
NQO2 and in kinases
In the structures of imatinib bound to its primary pharma-
cological target Abl [6-8,40], as well as to several other
kinases [10,41,42], the inhibitor binds in an extended
conformation, with the pyridylpyrimidine moiety (rings
A and B) trans to the methylbenzene and benzamide rings
(rings C and D) with respect to the C9-N13 bond (Fig 7A).
Nilotinib also binds to Abl in a similar extended confor-
mation [43]. Imatinib can also bind in a more compact
conformation, with the pyridylpyrimidine moiety cis to
the methylbenzene and benzamide rings (Fig 7B), as seen
in the structure of imatinib bound to Syk [44] and in the
structure of a desmethyl imatinib analogue bound to Src
[45]. This folded-over conformation is less common, and
is likely to correspond to a low-affinity interaction
because imatinib has limited efficacy against Syk [44]. The
conformation of the imatinib molecule in complex with
NQO2 resembles this cis conformation (Fig 7C). This may
have implications for the design of other pyridylpyrimi-
dine-containing kinase inhibitors and other drugs, which
might display unintended interaction with NQO2 if they
depend on or are capable of adopting a similar cis-like
conformation.
NQO2 phosphorylation
NQO2 is phosphorylated on either Ser 16 or Ser 20 in the
Bcr-Abl-positive cell line K562 [22]. To examine the
potential role of this modification in regulation of NQO2
activity, we mutated each residue to Ala or to phosphoser-
ine-mimicking Asp, purified the resulting proteins, and
measured their activities. As shown in Figure 8A, the
S16A, S20A, and S20D mutants exhibited ~70% of the
activity of the wild-type enzyme, while the activity of the
S16D mutant was reduced to ~10% of wild-type enzyme
activity. Additionally, the S16D mutant was colorless as
purified, as opposed to the yellow color displayed by the
other mutants and the wild-type protein, and was found
to be a mixture of monomer and dimer by analytical gel
filtration (data not shown).
Ser 16 and Ser 20 are both located adjacent to the binding
site for the FAD cofactor. Ser 20 is involved in recognition
of the FAD adenine ring (Figure 8B), so mutation at this
position might disrupt this interaction and reduce FAD
binding affinity, resulting in the lower activities of the
S20A and S20D mutants (Figure 8A). The side chain of Ser
16 forms a hydrogen bond with the main chain amide of
Gly 19 and packs against the imidazole side chain of His
11, keeping the main chain of Ser 16 from blocking part
of the FAD adenine binding site. The Ser 16 hydroxyl
group is also close to the diphosphate moiety of the FAD
(3.2 – 3.6 Å from the phosphate oxygen atoms to the Ser
16 Cβ atom) (Figure 8B). The S16A mutation might dis-
rupt the hydrogen-bonding and van der Waals interac-
tions necessary for proper formation of the adenine
binding pocket, resulting in a decrease in FAD binding
affinity similar to that caused by the Ser 20 mutations. The
pronounced drop in activity of the S16D mutant (Figure
8A), as well as the observed loss of yellow color and par-
tial monomerization, suggests loss of the FAD cofactor.
Such cofactor loss might result from repulsion between
the phosphate oxygen atoms of the FAD diphosphate
moiety and the aspartate side chain of the S16D mutant,
in addition to disruption of interactions necessary for
proper formation of the adenine binding pocket.
NQO1 active site is incompatible with imatinib bindingFigure 6
NQO1 active site is incompatible with imatinib bind-
ing. A) Model of imatinib in the active site of NQO1. The 
model was generated by superimposing the structure of 
human NQO1 (PDB ID 1D4A) onto the structure of the 
NQO2-imatinib complex. Imatinib (blue) is shown as a CPK 
model, while NQO1 is shown in surface and cartoon repre-
sentations, with the FAD cofactor and selected residues 
depicted as stick figures. The imatinib rings are lettered as in 
Figure 1A. Potential clashes between NQO1 residues and 
imatinib are highlighted in yellow.Page 8 of 12
(page number not for citation purposes)
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While the large decrease in the activity of the S16D mutant
suggests that phosphorylation of this residue could medi-
ate down-regulation of NQO2 activity, the buried nature
of the Ser 16 side chain likely precludes it from being a tar-
get for phosphorylation in cells. Furthermore, studies
have indicated that NQO2 is functional in K562 cells [26]
– the same cells in which NQO2 was found to be phos-
phorylated [22], suggesting that phosphorylation of
NQO2 is unlikely to be directly inactivating. Thus, it is
more likely that the solvent-exposed Ser 20 is the site of
NQO2 phosphoryation. The relatively minor effect of Ser
20 mutation on enzyme activity suggests that phosphor-
ylation may regulate some other aspect of NQO2 func-
tion, rather than by directly affecting enzyme activity. It is
worth noting that imatinib, and therefore Bcr-Abl inhibi-
tion, did not alter the phosphorylation of NQO2 on Ser
20 [22]. Therefore, the kinase that phosphorylates NQO2
is unlikely to be a direct Bcr-Abl effector.
Conclusion
To date, numerous crystal structures of the flavoprotein
oxidoreductase NQO2 in complex with quinones, natural
products, and xenobiotics have been solved [26,31,34-
37], and we report here the x-ray crystal structure of
NQO2 bound to the leukemia drug imatinib, an inhibitor
of Bcr-Abl. Our study has been motivated by the possibil-
ity that inhibitors of Bcr-Abl might also interact with
unintended targets, and that these interactions may lead
to side effects during drug treatment. The data reported in
this work elucidate the mechanism of NQO2 inhibition
by imatinib, and suggest that NQO2 is likely to be inhib-
ited by imatinib at the 1-μM serum concentration typical
in patients [14,27]. The question remains as to what the
physiological consequences of NQO2 inhibition by imat-
inib may be and whether they contribute to the efficacy of
imatinib in treatment of CML. While it has been reported
that RNAi knockdown of NQO2 or treatment with the
polyphenol NQO2 inhibitor resveratrol results in a reduc-
tion of proliferation of Bcr-Abl-positive K562 cells [26],
Comparison between imatinib-NQO2 and imatinib-kinase binding modesFigure 7
Comparison between imatinib-NQO2 and imatinib-kinase binding modes. A) The structure of imatinib bound to 
the kinase domain of Abl (PDB ID 1IEP) [6]. Imatinib binds in an extended conformation, with the pyridylpyrimidine moiety 
(rings A and B) trans to the methylbenzene and benzamide rings (rings C and D). B) The structure of imatinib bound to the 
kinase domain of Syk (PDB ID 1XBB) [44]. Imatinib binds in a compact conformation, with the pyridylpyrimidine moiety cis to 
the methylbenzene and benzamide rings. C) The conformation of imatinib bound to NQO2 most resembles the cis kinase-
binding conformation. Shown are the structures of imatinib from the Syk complex 1XBB (yellow), the Abl complex (green), and 
the NQO2 complex (blue), with their pyridylpyrimidine moieties superimposed. In all panels, proteins are shown in ribbon 
representation and imatinib is shown as a stick model. The imatinib rings are lettered as in Figure 1A.Page 9 of 12
(page number not for citation purposes)
BMC Structural Biology 2009, 9:7 http://www.biomedcentral.com/1472-6807/9/7we failed to see any effect of NQO2 knockdown on K562
cell proliferation (data not shown). On the other hand,
NQO2 knockout mice exhibit myeloid hyperplasia [46]
and increased susceptibility to chemical carcinogenesis
[47]. Although these side effects have not been observed
yet in CML patients treated with imatinib [48,49], future
studies on the effects of NQO2 inhibition on cellular
function and the role of NQO2 in cancer initiation and
progression may shed light on the possible physiological
consequences of NQO2 inhibition by imatinib or nilo-
tinib.
Methods
Expression and purification of recombinant NQO2
Full-length human NQO2 was cloned into the vector
pETM30 (EMBL-Heidelberg, Protein Expression Facility),
resulting in a His6-GST-NQO2 fusion protein with a TEV
protease cleavage site between GST and NQO2. The con-
struct was verified by sequencing and transformed into
Tuner(DE3)pLysS cells (Novagen) for protein expression.
Cells from 2 × 1 L expression cultures were harvested by
centrifugation, and cells were resuspended in buffer A (50
mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole).
Cells were lysed by sonication, and the lysate was cleared
by centrifugation at 200,000 g. The supernatant was
applied to a 5 mL HisTrap FF column (GE Healthcare)
equilibrated with buffer A, washed with buffer A until the
absorbance at 280 nm was stable, and eluted with 250
mM imidazole in buffer A. The eluted yellow protein was
desalted into buffer A and the His6-GST purification tag
was cleaved off using TEV protease. The protease and
His6-GST were removed from the NQO2 by passage back
over the HisTrap column. NQO2 was desalted into buffer
B (25 mM Tris-HCl pH 8.0, 25 mM NaCl) by concentra-
tion/dilution on a 5 K Amicon Ultrafree concentrator
(Millipore) and loaded onto a 5 mL HighTrap Q HP col-
umn (GE Healthcare). Protein was eluted with a gradient
of 0 – 500 mM NaCl in buffer B, and fractions containing
NQO2 (as ascertained by SDS-PAGE) were pooled, con-
centrated on a 5 K Amicon Ultrafree concentrator, and
stored at -20°C.
NQO2 activity assays
Activity of NQO2 was assayed using a continuous spectro-
photometric assay, adapted from previously reported
methods [22,28], with menadione as substrate and 1-car-
bamoylmethyl-3-carbamoyl-1,4-dihydropyrimidine
(CCHP) as co-substrate. Reduction of the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide
(MTT) was monitored at 590 nm using a SpectraMax M5
plate reader (Molecular Dynamics). Reaction were carried
out at 30°C in 200 μl containing 25 mM Tris-HCl pH 7.5,
0.01% Tween-20, 0.18 mg/ml BSA, 1 μM FAD, 100 μM
menadione, 0.134 mg/ml MTT, and 500 μM CCHP. Reac-
tions were initiated by addition of 20 ng recombinant
NQO2. For NQO2 inhibition assays, the respective inhib-
itors were pre-incubated with the recombinant NQO2
and reactions were started by the addition of substrate/co-
substrate. Slopes of the absorption-time-diagram were
used to calculate the specific activity. Each experiment was
repeated twice.
Electronic absorption spectroscopy
Imatinib stocks were prepared in dimethyl sulfoxide
(DMSO). NQO2 (18.3 μM) in 50 mM Tris-HCl pH 7.5
was mixed with imatinib (40 μM in 5% DMSO) or DMSO
and placed in a quartz cuvette. Electronic absorption spec-
Analysis of potential NQO2 phosphorylation sitesFigure 8
Analysis of potential NQO2 phosphorylation sites. A) 
Relative NQO2 activities of putative phosphorylation site 
mutants. Mutation of either Ser 16 or Ser 20 results in dimin-
ished activity, with the phosphorylation-mimicking S16D 
mutation having the most drastic effect. B) Ser 16 and Ser 20 
are located next to the binding site for adenine and diphos-
phate moieties of the FAD cofactor. Ser 20 is solvent-
exposed and involved in recognition of the FAD adenine 
moiety, while Ser 16 is mostly buried and involved in interac-
tions that help form the adenine binding site. The FAD cofac-
tor (yellow) and selected residues (green) are shown as stick 
models. Hydrogen bonds are depicted as dashed lines.Page 10 of 12
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ian) at 25°C. Data were collected over the range of 260–
700 nm at 600 nm/min with a 1 nm data point interval. A
buffer baseline was subtracted for each spectrum. Imat-
inib exhibits some absorption in this wavelength range
(data not shown), so the buffer for the imatinib sample
baseline also contained 40 μM imatinib. Difference spec-
tra were obtained by subtraction of the spectrum for the
sample containing NQO2 alone from the spectrum of the
sample containing imatinib.
Crystallization and X-ray data collection
NQO2 was thawed and desalted into 50 mM Tris-HCl pH
8.0, by three cycles of concentration/dilution on a 5 K
Amicon Ultrafree concentrator. Imatinib stocks were pre-
pared in DMSO. The NQO2-imatinib complex was
formed in a solution containing 50 mM Tris-HCl pH 8.0,
5 mM tris(2-carboxyethyl)phosphine, 1.15 mM NQO2,
and 1.5 mM imatinib, with a final concentration of 5%
DMSO. Crystals of the NQO2-imatinib complex were
grown in hanging drops at 20°C using the vapor diffusion
method. A volume of 1 μL of protein solution was mixed
with an equal volume of reservoir solution [62% (4R, S)-
2-methylpentane-2,4-diol (MPD) in 100 mM MES pH
6.0–6.2, 15 μM FAD] and allowed to equilibrate, and yel-
low rod-shaped crystals grew overnight. For X-ray diffrac-
tion experiments, crystals were transferred to a solution of
mother liquor (which already contained the cryoprotect-
ant MPD at a concentration of 62%), frozen, and stored in
liquid nitrogen. Diffraction data were collected at the
Advanced Light Source (Lawrence Berkeley National Lab-
oratory) beamline 8.2.1. Reflections were processed in
space group I422 with MOSFLM [50] and SCALA [51].
The structure was determined with the molecular replace-
ment program PHASER [52] using human NQO2 (PDB
ID 1QR2) [31] as the search model. The structure was
built using ARP/wARP [53], the model was improved
using COOT [54], and refinement was carried out using
PHENIX [55]. Model quality was analyzed using MOL-
PROBITY [56], and figures were drawn using the software
PYMOL [57]. The atomic coordinates and structure factors
have been deposited in the Protein Data Bank (3FW1).
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